EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Histologic transformation of non‐small‐cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms

Aya Shiba-Ishii iD, Noriko Takemura, Hitomi Kawai, Daisuke Matsubara

Cancer Science · 2024

DOI: 10.1111/cas.16192 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, 2024. Verfasst von Aya Shiba-Ishii und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Pathology, Institute of Medicine, University of Tsukuba, Tsukuba-shi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein Kinase Inhibitors, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the leading cause of cancer death and includes two major types: non‐small‐cell lung cancer (NSCLC) and small‐cell lung cancer (SCLC), accounting for 85% and 15% of cases, respectively. Non‐small‐cell lung cancer harboring actionable driver mutations is generally treated with tyrosine kinase inhibitors (TKIs) molecularly targeting individual oncogenes. Although TKIs have greatly contributed to better clinical outcomes, acquired resistance to them inevitably occurs. Histologic or lineage transformation is a rare but well‐documented off‐target mechanism associated with acquired resistance, and has been identified in settings following treatment with multiple different TKIs and other drugs. It includes neuroendocrine transformation, squamous cell transformation, and epithelial‐to‐mesenchymal transition. Here, we review the clinicopathologic features of transformed tumors and current understanding of the key genetic alterations and biologic mechanism of lineage transformation in NSCLC, particularly TKI‐triggered transformation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProtein Kinase InhibitorsLung NeoplasmsDrug Resistance, NeoplasmCell Transformation, NeoplasticEpithelial-Mesenchymal TransitionHumansMutationProtein-Tyrosine KinasesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

NSCLCSCLChistologic transformationlineage plasticitytyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsProtein-Tyrosine KinasesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Diagnostic Pathology, Institute of Medicine, University of Tsukuba, Tsukuba-shi, Japan.

ORCID-Profile: Aya Shiba-Ishii

Förderung

  • Takeda Science Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Shiba-Ishii, A., Takemura, N., Kawai, H., & Matsubara, D. (2024). Histologic transformation of non‐small‐cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms. Cancer Science. https://doi.org/10.1111/cas.16192

Vancouver

Shiba-Ishii A, Takemura N, Kawai H, Matsubara D. Histologic transformation of non‐small‐cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms. Cancer Science. 2024. doi:10.1111/cas.16192

BibTeX
@article{ShibaIshii2024,
  author = {Shiba-Ishii, Aya and Takemura, Noriko and Kawai, Hitomi and Matsubara, Daisuke},
  title = {Histologic transformation of non‐small‐cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16192}
}
Kostenlos starten →